BOSTON and COPENHAGEN, Nov. 30 /PRNewswire/ -- Exiqon A/S (NASDAQ OMX Copenhagen: "EXQ") announced today that the Harvard Medical School ICCB-Longwood Screening Facility (ICCB-L) has been recognized as a MicroRNA Screening Center of Excellence. ICCB-L supports investigators at Harvard Medical School, and associated hospitals and institutions, for high-throughput screening of small molecule and RNAi libraries.
MicroRNAs are a novel class of small, non-coding RNA species, which have been shown to play a major role in post-transcriptional processing of messenger RNA, including the regulation of many physiological and pathological processes, such as cellular development, cancer, apoptosis, aging, metabolic diseases, and immune responses. The external modulation of microRNA expression levels has been shown to have dramatic impact on cellular phenotype, a result which has promoted the functional analysis of microRNA to the forefront of translational medicine.
ICCB-L will provide the Exiqon LNA(TM) microRNA Knockdown Library as a screening tool for a new consortium of Harvard-affiliated investigators, coordinated by Dr. Neil Kubica of the Blenis Laboratory at Harvard Medical School. The consortium has developed multiple biological models that will be interrogated with the Knockdown Library. The Library contains over 900 specific inhibitors designed for uniform potency, made possible through the incorporation of Exiqon's proprietary LNA(TM) technology.
"My colleagues and I look forward to screening the Knockdown Library. There is a great deal of interest in our community in using miRNA knockdown reagents to study disease-related biology," says Dr. Kubica.
Exiqon recently unveiled its microRNA Centers of Excellence Program -- which has categories for microRNA Profiling (Expression), microRNA detection and imaging (Localization), and microRNA functional studies (Screening) -- to help provide a set of reference laboratories and institutions for researchers new to the field of microRNA study. "More and more researchers are recognizing the importance and relevance of microRNA in their own biological systems under study. But with a variety of methods and solutions from different providers, sometimes researchers aren't sure where to start. It can be overwhelming," says Tom Bishop, Site Director for Exiqon North America. "The microRNA Centers of Excellence are meant to be a roadmap of sorts for researchers new to microRNA -- a panel of experts who demonstrate best-in-class tactics and approaches to microRNA studies."
The microRNA Centers of Excellence Program serves as an example of the collaborative spirit in which microRNA research has blossomed over recent years, according to Exiqon officials. "Exiqon has always been committed to bringing exceptional value in the tools and solutions we provide microRNA researchers, but this is only one piece of the puzzle," says Chris Harbert, Director of Marketing for Exiqon North American Life Sciences. "The real magic occurs when excellence in research tools is combined with excellence in experimental design and implementation. That's what these microRNA Centers of Excellence will bring to the table."
ICCB-L represents the first institution to be inducted as an Exiqon microRNA Center of Excellence, in the area of functional studies. Exiqon is currently accepting other Center of Excellence applications in all categories. Interested parties are invited to contact their local representative, or to contact Chris Harbert, Director of Marketing, at (888) 647-2879.
Exiqon operates in two business segments sharing one vision: the idea of taking science to patients through personalized medicine; one focus: the promise of miRNA as biological markers; and one technology platform: our proprietary LNA(TM) (Locked Nucleic Acid) detection technology with its unique competitive advantages in the markets we address. Exiqon Life Sciences has established a position for itself as one of the market's leading providers of research products for gene expression analysis. Our products are used by academia, biotech and pharmaceutical companies around the world to make groundbreaking discoveries in the field of gene expression analysis. Exiqon Life Sciences is also collaborating with pharmaceutical companies in their effort to develop new medicines based on biological markers (Pharma Services). Exiqon Diagnostics is a leading provider of cellular based diagnostics for cancer treatment selection. We are developing a series of new molecular diagnostic tests for high incidence cancers based on miRNA biomarkers. The first test has been developed, and additional tests are in the pipeline for each coming year. Exiqon has approximately 170 employees and is listed on the NASDAQ OMX in Copenhagen. For more information about Exiqon, visit www.exiqon.com.
This announcement contains forward-looking statements regarding Exiqon's potential future development and financial performance and other statements which are not historical facts. Such statements are made on the basis of assumptions and expectations which, to the best of Exiqon's knowledge, are reasonable and well-founded at this time, but which may prove to be erroneous. Exiqon's operations are characterized by the fact that its actual results may deviate significantly from that described herein as anticipated, believed, estimated or expected.
Contact: Chris Harbert Exiqon Director of Marketing 888-647-2879 email@example.com
Copyright©2009 PR Newswire.
All rights reserved